VYNE TherapeuticsVYNE
VYNE
About: VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Employees: 13
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
114% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 7
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
9% more funds holding
Funds holding: 35 [Q4 2024] → 38 (+3) [Q1 2025]
0.81% less ownership
Funds ownership: 47.9% [Q4 2024] → 47.09% (-0.81%) [Q1 2025]
51% less capital invested
Capital invested by funds: $23.4M [Q4 2024] → $11.5M (-$12M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4.50
400%
upside
Avg. target
$4.50
400%
upside
High target
$4.50
400%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 400%upside $4.50 | Buy Maintained | 25 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the quarter ended March 31, 2025, and provided a business update.
Negative
Benzinga
1 month ago
FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold
The U.S. Food and Drug Administration (FDA) on Friday verbally informed that it placed a clinical hold on VYNE Therapeutics Inc.'s VYNE Phase 1b study evaluating VYN202 for the treatment of moderate-to-severe plaque psoriasis.
Neutral
GlobeNewsWire
1 month ago
VYNE Therapeutics Provides Update on VYN202 Program
BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company that it placed a clinical hold on the Company's Phase 1b study evaluating VYN202 for the treatment of moderate-to-severe plaque psoriasis. The clinical hold determination was made following a recent observation of testicular toxicity in dogs from a non-clinical toxicology study with VYN202.
Neutral
GlobeNewsWire
2 months ago
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE's management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 27, 2025.
Neutral
GlobeNewsWire
3 months ago
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the fourth quarter and year ended December 31, 2024, and provided a business update.
Neutral
GlobeNewsWire
3 months ago
VYNE Therapeutics to Participate in March Investor Conferences
BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE's management will participate in two investor conferences in March.
Neutral
GlobeNewsWire
3 months ago
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that the first subject has been dosed in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases. The Phase 1b trial will primarily evaluate the safety of VYN202, administered orally once a day for 12 weeks, with secondary objectives to evaluate the pharmacokinetic profile and preliminary evidence of efficacy, including improvement from baseline in psoriasis area and severity index (PASI) scores. Top-line data from the 12-week randomized, placebo-controlled trial are expected by year-end 2025.
Neutral
GlobeNewsWire
5 months ago
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced completion of enrollment in the Phase 2b trial evaluating VYN201 gel for the treatment of nonsegmental vitiligo. Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025.
Neutral
GlobeNewsWire
5 months ago
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
BRIDGEWATER, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive results from the multiple ascending dose (“MAD”) portion of its Phase 1a SAD/MAD trial of VYN202. The Phase 1a trial was a two-part, double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of single ascending dose (“SAD”) and MAD components to evaluate the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics of VYN202.
Negative
Zacks Investment Research
7 months ago
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $1.85 per share a year ago.
Charts implemented using Lightweight Charts™